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Introduction: The relationship between the EGFR gene mutation
status and clinical outcome has not fully been assessed in patients
with non-small cell lung cancer (NSCLC) who received cytotoxic
agents. The aim of this study was to clarify its association. We also
examined whether this association could be affected by previous
gefitinib treatment.
Methods: Patients with advanced or postoperative recurrent
NSCLC who received both cytotoxic chemotherapy and gefitinib
monotherapy in their treatment course were included in this study.
An EGFR mutation was determined in exons 19 and 21 by direct
sequencing.
Results: Of 194 Japanese patients with advanced or relapsed
NSCLC assessable for mutation analysis, 60 received both cytotoxic
chemotherapy and gefitinib monotherapy through their treatment
courses. EGFR mutations significantly affected progression-free
survival (PFS) in the first-line cytotoxic chemotherapy regimens in
the multivariate analysis (hazard ratio for PFS  0.422; p 
0.0422). In contrast, in 28 (47%) of the 60 patients who also
received cytotoxic chemotherapy after the relapse to gefitinib mono-
therapy, there were no differences in PFS stratified by EGFR
mutation status. The sensitivity to gefitinib was, however, correlated
with EGFR mutation status, and its sensitivity was retained even in
the second-line treatment setting in patients with EGFR mutations.
Conclusions: EGFR mutations were therefore significantly associ-
ated with a better PFS in the first-line cytotoxic chemotherapy
regimens. However, its association was not observed in the cyto-
toxic regimens administered after the relapse to gefitinib mono-
therapy, whereas gefitinib sensitivity was associated with an EGFR
mutation even in the second-line or later treatment settings.
Key Words: Lung cancer, Gefitinib, EGFR mutation.
(J Thorac Oncol. 2007;2: 632–637)
The epidermal growth factor receptor (EGFR) is a promisingtarget for anticancer therapy because EGFR signaling is
known to be associated with proliferation and survival of cancer
cells and it is frequently overexpressed in a variety of tumors
including non-small cell lung cancer (NSCLC).1 Several re-
searchers have suggested the possible association between
EGFR function and sensitivity to cytotoxic chemotherapy. Dixit
et al.2 demonstrated that decreased expression of the EGFR in
MDA-MB-468 breast cancer cells resulted in a reduced sensi-
tivity to cisplatin.2 It was shown that sensitivity to other cyto-
toxic agents including anthracyclines, vinca alkaloids, and flu-
orouracils could be also modified by EGFR expression level.3
As a whole, the EGFR function seems to have a certain rela-
tionship with the sensitivity to cytotoxic agents.
As a molecular oncologic alteration, somatic mutations
in the tyrosine kinase domain of the EGFR gene have been
recently found in NSCLC patients as gain-of-function onco-
genic mutations.4 Several studies in transfected cells and
human lung cancer cell lines have shown the mutant EGFR
receptor to lead to a constitutive activation of the downstream
signaling pathways, thus suggesting these alterations poten-
tially confer sensitivity to EGFR tyrosine kinase inhibitors in
EGFR mutant tumor cells,4–6 although no detailed mecha-
nisms of its action have not yet been defined.
Gefitinib, EGFR tyrosine kinase inhibitor, has clini-
cally shown promising antitumor activity in relapsed NSCLC
patients of East Asian origin in phase II and III trials.7,8 The
association between the EGFR gene mutation status and
responsiveness to gefitinib has been extensively studied in the
clinical setting, and we and other investigators demonstrated
that EGFR mutant tumors yielded a high sensitivity to ge-
fitinib as observed in preclinical studies9–11; however, the
influence of EGFR mutations on the responsiveness to cyto-
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toxic agents has not been fully investigated yet. Based on this
background, we investigated whether the EGFR mutation
status was associated with the efficacy of first-line cytotoxic
chemotherapy in relapsed or advanced NSCLC patients.
In addition to these conventional EGFR mutations, the
emergence of a second mutation at EGFR codon 790 at the
time of relapse to gefitinib treatment was recently found,
which is now considered to correlate with gefitinib resis-
tance.12 The effect of cytotoxic reagent on T790M mutant
tumor cell remains unknown; furthermore, the gefitinib-re-
sistant cells induced by gefitinib treatment may acquire some
features that cause higher resistance to cytotoxic reagents
compared with gefitinib-naive tumor cells.13 It may indicate
that gefitinib exposure might modulate the original associa-
tion between EGFR mutation status and responsiveness to
subsequent cytotoxic chemotherapy. We therefore also exam-
ined whether this association could be affected by the previ-
ous gefitinib treatment.
MATERIALS AND METHODS
A total of 194 patients with advanced or postoperative
recurrent NSCLC who were admitted to Okayama University
Hospital between January 1999 and December 2005 were
assessable for EGFR mutation analysis. Of these, 60 (31.4%)
patients underwent both cytotoxic chemotherapy and gefitinib
monotherapy through their treatment courses. Informed con-
sent was obtained from all patients. Tumor response was
assessed as complete response (CR), partial response (PR), no
change (NC), or progressive disease (PD) in accordance with
the World Health Organization Criteria.14
Genomic DNA was extracted from frozen or paraffin-
embedded specimens, and the mutation status of the EGFR
tyrosine kinase domain (exons 19 and 21) was examined with
the direct sequence method described in the previous report.11
In brief, polymerase chain reaction (PCR) amplification for
extracted DNA was done using HotStarTaq DNA polymerase
(Qiagen Inc., Valencia, CA) with the specific primers and PCR
conditions. PCR products were incubated using ExoSAP-IT
(Amersham Biosciences Corp., Piscataway, NJ) and sequenced
directly using Applied Biosystems PRISM dye terminator cycle
sequencing method (Perkin-Elmer Corp., Foster City, CA) with
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Fos-
ter City, CA).
The associations between the EGFR mutation status
and the responses to cytotoxic agents and gefitinib were
evaluated by 2 test or Fisher’s exact test. The progression-
free survival (PFS) time was defined as the time from initi-
ation of cytotoxic chemotherapy or gefitinib treatment until
the day of documented disease progression. The overall
survival time was also defined as the time from initiation of
first-line chemotherapy to the time of death from any cause or
to the date that the patient was last known to be alive. These
survival curves were constructed using the Kaplan-Meier
product-limit method. Any differences between the curves
were evaluated by the log-rank test. Proportional hazard
regression models were applied to evaluate potential impact
of confounders (covariates: EGFR mutation, gender, disease
stage, histology, Brinkman index, which was calculated as
follows: [average number of cigarettes consumed daily] 
[number of years of smoking]), and the performance status at
initiation of each chemotherapy). p values 0.05 were con-
sidered to be statistically significant.
RESULTS
Demographics of Patients and Treatment
Regimens
The demographics of the 60 NSCLC patients are listed
in Table 1. Seventeen patients (28%) had tumors harboring
EGFR mutations. In-frame deletion in exon 19 was observed
in six patients (35%), and the remaining 11 (65%) had a point
mutation (L858R) in exon 21. As expected, the majority of
the patients with mutations were female and had adenocarci-
noma histology and never-smoking history.
Of the 60 patients, 54 (90%) received cytotoxic che-
motherapy in the first-line treatment setting, and gefitinib
monotherapy was administered in the later treatment settings.
In the remaining six patients (10%) who underwent gefitinib
therapy in the first-line treatment setting, cytotoxic agents
were subsequently administered after the gefitinib therapy.
The treatment regimens are shown in Table 2. Their types
were almost comparable between patients with or without an
EGFR mutation. Fifty-eight percents of the regimens in the
first-line treatment were platinum-based combination chemo-
therapy (58%), while about two third of chemotherapy regi-
TABLE 1. Demographics at Time of Initiation of First Cytotoxic Chemotherapy through the Treatment Course in 60 Patients
Patients with EGFR Mutations
(n  17, 28%)
Patients without EGFR Mutations
(n  43, 72%) Total Patients (n  60)
Median age, yr (range) 60 (28–77) 66 (33–82) 65 (28–82)
Gender, male/female 5 (29%)/12 (71%) 30 (70%)/13 (30%) 35 (58%)/25 (42%)
Histology (Ad/BAC/Sq/others) 16 (94%)/1 (6%)/0/0 28 (65%)/2 (5%)/10 (23%)/3 (7%) 44 (73%)/3 (5%)/10 (17%)/3 (5%)
Disease stage (IIIB/IV/rec) 0/3 (18%)/14 (82%) 6 (14%)/17 (40%)/20 (47%) 6 (10%)/20 (33%)/34 (57%)
Smoking history, yes/no 4 (24%)/13 (76%) 34 (79%)/9 (21%) 38 (63%)/22 (37%)
Median Brinkman index (range) 0 (0–800) 550 (0–2820) 400 (0–2820)
Performance status (0/1/2) 5 (29%)/10 (59%)/2 (12%) 11 (26%)/29 (67%)/3 (7%) 16 (27%)/39 (65%)/5 (8%)
Ad, adenocarcinoma; BAC, bronchioloalveolar carcinoma; Sq, squamous cell carcinoma; rec, postoperative recurrence.
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mens administered after gefitinib treatment did not contain
any platinum agents (64%).
Gefitinib was orally administered at a dose of 250 mg
once daily in six (10%), 36 (60%), 15 (25%), and three (5%)
patients as the first-, second-, third-, and fourth-line treatment
settings among the 60 patients, respectively.
Efficacy of Cytotoxic Chemotherapy
The objective response to first-line cytotoxic chemo-
therapy was obtained in nine (16.7%; 95% confidence inter-
val [CI]: 6.4%–26.9%) of the 54 patients. The median length
of follow-up of the 19 surviving patients was 41.5 months
(range, 1.7–90.7), and the 6-month and 1-year PFS rates and
6-month and 1-year overall survival rates in the first-line
cytotoxic chemotherapy were 28.0%, 4.7%, 88.7%, and
71.5%, respectively. Regarding the efficacy of chemotherapy
administered after gefitinib monotherapy in the 28 patients,
the objective response rate and 6-month PFS rates were
25.0% (seven of 28 patients; 95% CI: 7.9%–42.1%) and
16.2%, respectively.
Association between EGFR Mutation Status
and Efficacy of First-line Cytotoxic
Chemotherapy
We investigated whether EGFR mutation status was
associated with sensitivity to first-line cytotoxic chemother-
apy in the 54 patients. The objective response to cytotoxic
chemotherapy was not influenced by EGFR mutation status
(three [21%] of 14 patients with an EGFRmutation versus six
[15%] of 40 wild-type patients, respectively; p  0.6842). In
addition, neither smoking status nor types of EGFRmutations
affected response to chemotherapy. However, EGFR muta-
tions tended to yield a better PFS (log-rank test; p  0.0535),
with 6-month PFS rates of 45.8% and 21.9%, respectively
(Figure 1A). This difference was also found based on the
findings of a multivariate analysis (hazard ratio [HR] 
0.422, 95% CI: 0.179–0.991, p  0.0422; Table 3). The
EGFR mutation status also significantly correlated with the
overall survival after initiation of first-line cytotoxic chemo-
therapy in both univariate (Figure 2) and multivariate analy-
ses (HR  0.263, 95% CI: 0.099–0.699, p  0.0074; Table
TABLE 2. Treatment Regimens
First-line Regimens Cytotoxic Regimens after Gefitinib Therapya
Mutation (n  17) No Mutation (n  43) Mutation (n  11) No Mutation (n  17)
Type of regimens
Cytotoxic agent therapy 14 40 11 17
Platinum based 11 (65%) 24 (56%) 3 (27%) 7 (41%)
Cisplatin plus new agents 8 12 0 1
Carboplatin plus new agents 3 11 3 6
Other platinum combination 0 1 0 0
Nonplatinum based 3 (18%) 16 (37%) 8 (72%) 10 (59%)
Single new agentb 1 6 7 6
Combination 2 10 1 4
Gefitinib monotherapy 3 (18%) 3 (7%) — —
a Twenty-eight of the 60 patients received cytotoxic chemotherapy after gefitinib monotherapy as the second-line or later treatment settings.
b Docetaxel, paclitaxel, vinorelbine, gemcitabine, and irinotecan were defined as newer chemotherapeutic agents.18
FIGURE 1. Progression-free survival curves after initiation of first-line cytotoxic chemotherapy in the 54 patients (A), cyto-
toxic chemotherapy administered after gefitinib monotherapy in the 28 patients (B), and gefitinib monotherapy as the sec-
ond-line or later treatment settings in the 54 patients (C). Bold and thin lines represent survival in patients with and without
EGFR mutations, respectively. Log-rank test; p  0.0535 (A), p  0.6844 (B), and p  0.0001 (C)).
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3). Smoking status did not affect the PFS after the adminis-
tration of cytotoxic chemotherapy.
Association between EGFR Mutation Status and
Efficacy of Cytotoxic Chemotherapy
Administered after Gefitinib Monotherapy
We next focused on the association between the EGFR
mutation status and clinical outcomes after initiation of cy-
totoxic chemotherapy administered after gefitinib treatment.
A total of 28 patients received cytotoxic chemotherapy after
gefitinib monotherapy in the second-line or later treatment
settings (Table 2). Of these, objective responses to cytotoxic
chemotherapies after gefitinib treatment tended to be higher
in patients with an EGFR mutation than in patients without
any mutation (45% and 12%, respectively; p  0.0764).
There was, however, no difference in PFS between the two
groups (log-rank test; p 0.6844), with 6-month PFS rates of
23% and 13%, respectively (Figure 1B).
Efficacy of Gefitinib Monotherapy
As expected, in all 60 patients, the gefitinib sensitivity
was significantly affected by EGFR mutation status with
objective response rates of 76% and 16% (p  0.0001) and
6-month PFS rates of 88% and 23% (p  0.0001) in those
with and without mutations, respectively. Even in the second-
line or later treatment settings, after the administration of
cytotoxic chemotherapy, a higher response rate (p  0.0001)
and better PFS (p  0.0001) were observed in the EGFR-
mutant patients than those in wild-type, with objective re-
sponse rates of 92% versus 18% and 6-month PFS rates of
100% versus 22%, respectively (Figure 1C).
DISCUSSION
In this study, we found that EGFR mutation was asso-
ciated with the survival time from initiation of first-line
cytotoxic chemotherapy ( Figures 1A and 2). In the phase III
INTACT trials for advanced NSCLC patients, Bell et al.15
also demonstrated that PFS was better for EGFR mutation–
positive patients than for those without mutations in the
first-line treatment of platinum-based chemotherapy. A sub-
group analysis of the TRIBUTE study, comparing erlotinib
with placebo in combination with cytotoxic chemotherapy,
also demonstrated that among the patients treated with cyto-
toxic chemotherapy alone, better PFS was observed in the
EGFR mutation–positive patients.16 Based on these data, a
certain interaction seems to exist between EGFR mutations
and sensitivity to cytotoxic chemotherapy, similar to the
positive association between EGFR function and responsive-
ness to cytotoxic chemotherapy shown in the previous stud-
ies.2,3 However, we do not know the detailed mechanism of
how cytotoxic agents work differently in EGFR mutant and
wild-type tumors only with our current data; therefore, future
molecular analyses are needed to support its relationship.
In contrast, we also found PFS after initiation of cyto-
toxic chemotherapy administered after gefitinib treatment not
to be affected by the EGFR mutation status (Figure 1B); this
different influence of EGFR mutation status between the two
periods should be simply attributable to our small sample size
or the difference in types of chemotherapy regimens. How-
ever, as another explanation for this observation, a second
mutation through the continuous gefitinib treatment might
modulate the primarily positive association between EGFR
mutation and the efficacy in cytotoxic chemotherapy. Indeed,
recent reports have shown that exposure to gefitinib induced
TABLE 3. Multivariate Analysis for Survival after Initiation of the First-line Cytotoxic Chemotherapy
Progression-free Survival Overall Survival
Factors HR 95% CI p HR 95% CI p
EGFR mutation (yes vs. no) 0.422 0.179–0.991 0.0475 0.263 0.099–0.699 0.0074
Tumor histology (adenocarcinoma vs. others) 1.384 0.633–3.023 0.4153 1.096 0.469–2.558 0.8325
Gender (female vs. male) 0.651 0.243–1.742 0.3925 0.705 0.239–2.077 0.5257
Disease stage (stage IV vs. others)a 0.955 0.459–1.986 0.9017 0.984 0.460–2.102 0.9660
Performance status (0 vs. 1 or worse)b 0.529 0.254–1.103 0.0896 0.471 0.184–1.208 0.1172
Brinkman index (400 vs. 400)c 2.067 0.759–5.631 0.1554 0.975 0.352–2.701 0.9618
HR, hazard ratio; CI, confidence interval.
a At initiation of first-line chemotherapy.
b At initiation of each chemotherapy.
c Median Brinkman index was applied as the cutoff level.
FIGURE 2. Overall survival curve after initiation of first-line
cytotoxic chemotherapy in the 54 patients. Bold and thin
lines represent survival in patients with and without EGFR
mutations, respectively (log rank test; p  0.0025).
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the appearance of gefitinib-resistant cells with alterations in
some intercellular signal transduction pathways.13 These al-
terations might thus influence the cellular response to cyto-
toxic reagents, although the precise mechanism remains un-
clear. To clarify these issues, whole EGFR mutation analyses
through exon 18 to 21 should thus be performed both before
and after gefitinib treatment using a large cohort.
The current treatment guidelines recommend that ge-
fitinib should be used after cytotoxic chemotherapy in uns-
elected patients with advanced NSCLC.17 Recently, Inoue et
al.18 conducted a Japanese phase II trial of first-line single-
agent treatment with gefitinib for advanced NSCLC patients
harboring EGFR mutations. It is interesting to note that
gefitinib treatment yielded a favorable response rate of 75%
and a median PFS time of 9.7 months. Contrary to these
findings, our findings might support that patients who harbor
EGFR mutations thus seem to still benefit from the early use
of cytotoxic chemotherapy before gefitinib administration in
their NSCLC treatment courses because of the significantly
better PFS in the first-line cytotoxic chemotherapy in EGFR
mutation–positive patients (Figure 1A). In addition, high
sensitivity to gefitinib was indeed retained even in second-
line or later treatment settings in patients with EGFR muta-
tions in this study (Figure 1C). Our findings suggest that an
optimal sequence of gefitinib therapy and cytotoxic chemo-
therapy should be extensively investigated taking EGFR
mutation status into consideration, although the relevant ran-
domized trials evaluating the optimal sequence do not stratify
the patients according to the EGFR mutation status.19
As a major critical point in this study, the better PFS in
the first-line cytotoxic chemotherapy in EGFR-mutation–
positive patients might be essentially attributable to a favor-
able natural history in this genetically defined subset of
NSCLC, irrespective of the efficacy of chemotherapy itself.20
Several investigators have demonstrated that classic EGFR
mutations confer a favorable prognosis and that the superior
survival reported for mutation-positive patients treated with
tyrosine kinase inhibitors from single-arm studies,21 although
majority of them were based on the retrospective analyses of
highly selected and heterogeneous patients. In addition, a
significantly longer survival time has been recently reported
for untreated mutation-positive patients.22 Therefore, one can
criticize that this superior survival reported for mutation-
positive patients may not be derived as a direct result of the
differential effect of therapy on the subgroup populations.
However, it is also true that a better overall survival in
mutation-positive NSCLC patients was not always evi-
dent.23,24 These observations still make it confusing regarding
whether the EGFR mutation itself directly influences the
natural history of NSCLC. Therefore, determining whether
the EGFR-mutant NSCLC bears a more favorable prognosis
regardless of therapy awaits further carefully designed pop-
ulation studies. Other limitations are that our analysis was
based on a retrospective review with an unplanned analysis in
a small patient cohort and that there might also be a potential
bias for patient selection. Furthermore, the problems included
the lack of a uniform procedure for patient follow-up. All of
them might interfere with the suitability of the statistical
analyses. However, if these limitations are understood, our
results are hypothesis generating, which raises a critical point
that needs to be evaluated in future studies.
In conclusion, we found the clinical outcome after
initiation of first-line cytotoxic chemotherapy to significantly
differ according to the EGFR mutation status. However, its
association was not observed in the cytotoxic regimens ad-
ministered after the relapse with gefitinib monotherapy,
whereas gefitinib sensitivity was associated with EGFR mu-
tations, even in the second-line or later treatment settings.
Further investigations are thus warranted to confirm this
observation in large-scale clinical trials.
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